Andrew J. Sleight

5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential

Joel R. Martin, Michael Bös, F. Jenck et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 334 citations

Prolonged sedation due to accumulation of conjugated metabolites of midazolam

Tilman Bauer, R Ritz, C. Haberthür et al. · The Lancet · 1995 · 333 citations

Medicine, Conjugated Metabolites, Anesthesia Practice +7

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

Cem Gabay, Bruno Fautrel, Jürgen Rech et al. · Annals of the Rheumatic Diseases · 2018 · 284 citations · Full text

A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze

Marie L. Woolley, Jane Bentley, Andrew J. Sleight et al. · Neuropharmacology · 2001 · 200 citations

Synaptic Plasticity, Cognitive Science, Neurobiological Mechanism +12

5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism

Madeleine V. King, Andrew J. Sleight, Marie L. Woolley et al. · Neuropharmacology · 2004 · 192 citations

Synaptic Plasticity, Novel Object Discrimination, Nmda Receptor Antagonism +12